Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans

Translated title of the contribution: Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans

A. Baars, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5% of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.

Translated title of the contributionGood response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans
Original languageDutch
Pages (from-to)2072-2076
Number of pages5
JournalNederlands Tijdschrift voor Geneeskunde
Volume147
Issue number42
StatePublished - Oct 18 2003
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans'. Together they form a unique fingerprint.

  • Cite this